| PRECIGEN INC. |
| USA |
| Gesundheit |
| US74017N1054 / A2PZG1 |
| I5X (Frankfurt) / PGEN (NASDAQ) |
| FRA:I5X, ETR:I5X, I5X:GR, NASDAQ:PGEN |
| - |
| https://precigen.com/ |
|
Precigen Inc. is a biopharmaceutical company focused on developing precision medicines for difficult-to-treat diseases. The company applies gene and cell therapy platforms to create targeted programs in immuno-oncology, autoimmune disorders, and infe..
>Volltext.. |
| 2465.86 Mio. EUR |
| 2518.64 Mio. EUR |
| 75.59 Mio. EUR |
| -31.18 Mio. EUR |
| -139.07 Mio. EUR |
| -0.96 EUR |
| 86.72 Mio. EUR |
| 14.4 Mio. EUR |
| -100.68 Mio. EUR |
| 1.3 |
| 1937.18% |
| -30.66% |
| - |
| - |
| - |
| - |
| PRECIGEN |
| 01.10.26 |
|
||||
|